These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 26423340)

  • 1. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on research activity in the USA on Cancer Precision Medicine.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
    Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).
    Massett HA; Mishkin G; Moscow JA; Gravell A; Steketee M; Kruhm M; Han SH; Barry B; Montello M; Zwiebel J; Abrams JS; Doroshow JH; Ivy SP
    Clin Cancer Res; 2019 Dec; 25(23):6925-6931. PubMed ID: 31439585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCI-MATCH launch highlights new trial design in precision-medicine era.
    McNeil C
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
    [No Abstract]   [Full Text] [Related]  

  • 11. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Ivy SP; Siu LL; Garrett-Mayer E; Rubinstein L
    Clin Cancer Res; 2010 Mar; 16(6):1726-36. PubMed ID: 20215542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
    Simon R
    Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design.
    Ha H; Lee HY; Kim JH; Kim DY; An HJ; Bae S; Park HS; Kang JH
    Cancer Res Treat; 2024 Oct; 56(4):991-1013. PubMed ID: 38726510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
    Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
    J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 18. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
    Yada S; Hamada C
    Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.